Alnylam completes upsized $805M follow-on

On Nov. 16, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) raised $805 million through the sale of 6.4 million shares at $125 in a bumped-up follow-on underwritten by Goldman Sachs, JPMorgan, Barclays, Credit Suisse, Piper Jaffray, JMP Securities, Needham, Chardan and B. Riley FBR. The company had proposed to raise $675 million.

By year end, Alnylam plans to submit an NDA to FDA and MAA to EMA for patisiran (ALN-TTR02) to treat familial amyloidotic polyneuropathy (FAP), a form of transthyretin (TTR) amyloidosis...